Consilium 10th Annual Healthcare Conference UK w/ Nick Keher

Join BenevolentAI’s CFO, Nick Keher, at Consilium Strategic Communications 10th Annual Healthcare Conference 2022

Monday 14th November 2022 | 1.05pm BST

Ultimately we need to be bringing significant innovation to patients and supporting physicians to radically change treatment protocols - but does the industry skew too much towards what makes most financial sense? In this panel, Nick Keher will discuss whether ‘hot therapeutic areas of investor focus are a help or a hindrance to innovation’.

  • Nicola Maguire, Partner, Cooley - Moderator
  • Nick Keher, CFO, Benevolent AI
  • Richard Francis, CEO, Purespring Therapeutics
  • Ros Deegan, CEO, OMass Therapeutics
  • Linden Thomson, Fund Manager, AXA Investment Managers UK
  • Lars Wilde, CEO, Pangea Botanica

Learn more about this event →

Nick Keher

Chief Financial Officer

Nick joined Benevolent AI as CFO in March 2022, having previously been CFO of Clinigen, a UK AIM listed Global Pharmaceutical and Pharma Services company with over £450m of revenue. Prior to this Nick was an equity analyst covering the European healthcare space for over eight years, first at Investec and then at RBC where he was Managing Director and Head of RBC’s European healthcare equity research team. Nick began his career at Lloyd’s Pharmacy, registering as a pharmacist before joining GlaxoSmithKline (‘GSK’) where he completed his accountancy qualification (ACMA) working within GSK’s finance function

More Posts

You Might Also Like

BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022